MY117969A - Agent with an antidepressive effect comprising pramipexole and sertraline - Google Patents

Agent with an antidepressive effect comprising pramipexole and sertraline

Info

Publication number
MY117969A
MY117969A MYPI99002869A MYPI9902869A MY117969A MY 117969 A MY117969 A MY 117969A MY PI99002869 A MYPI99002869 A MY PI99002869A MY PI9902869 A MYPI9902869 A MY PI9902869A MY 117969 A MY117969 A MY 117969A
Authority
MY
Malaysia
Prior art keywords
pramipexole
sertraline
agent
antidepressive effect
antidepressive
Prior art date
Application number
MYPI99002869A
Other languages
English (en)
Inventor
Jerzy Prof Dr Maj
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MY117969A publication Critical patent/MY117969A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI99002869A 1998-07-07 1999-07-07 Agent with an antidepressive effect comprising pramipexole and sertraline MY117969A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung

Publications (1)

Publication Number Publication Date
MY117969A true MY117969A (en) 2004-08-30

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI99002869A MY117969A (en) 1998-07-07 1999-07-07 Agent with an antidepressive effect comprising pramipexole and sertraline

Country Status (32)

Country Link
US (1) US6255329B1 (https=)
EP (1) EP1093369B1 (https=)
JP (1) JP2002520273A (https=)
KR (1) KR100557692B1 (https=)
CN (1) CN1230168C (https=)
AR (1) AR019896A1 (https=)
AT (1) ATE228365T1 (https=)
AU (1) AU762128B2 (https=)
BG (1) BG64972B1 (https=)
BR (1) BR9911768A (https=)
CA (1) CA2336833C (https=)
CZ (1) CZ294087B6 (https=)
DE (2) DE19830201A1 (https=)
DK (1) DK1093369T3 (https=)
EA (1) EA003142B1 (https=)
EE (1) EE04296B1 (https=)
ES (1) ES2183583T3 (https=)
HU (1) HUP0103922A3 (https=)
ID (1) ID27776A (https=)
IL (1) IL140603A0 (https=)
MY (1) MY117969A (https=)
NO (1) NO20010064L (https=)
NZ (1) NZ509729A (https=)
PL (1) PL195043B1 (https=)
PT (1) PT1093369E (https=)
RS (1) RS49795B (https=)
SK (1) SK284923B6 (https=)
TR (1) TR200100146T2 (https=)
TW (1) TW592698B (https=)
WO (1) WO2000002542A2 (https=)
YU (1) YU401A (https=)
ZA (1) ZA200100090B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. キラル精製置換ベンゾチアゾールジアミンの合成
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US20120115871A1 (en) * 2009-04-30 2012-05-10 Supemus Pharmaceuticals, Inc Method of treatment of depression
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
ES2950875T3 (es) 2012-02-08 2023-10-16 Supernus Pharmaceuticals Inc Formulaciones de liberación modificada de viloxazina
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CA3104811C (en) * 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
EA001485B1 (ru) * 1996-03-29 2001-04-23 Пфайзер Инк. Производные бензил(иден)-лактамов, их получение и применение в качестве селективных (ант)агонистов рецепторов 5-htи/или 5-ht
AU734872B2 (en) * 1996-12-02 2001-06-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
SK284923B6 (sk) 2006-02-02
PL195043B1 (pl) 2007-08-31
ZA200100090B (en) 2002-04-04
CN1308533A (zh) 2001-08-15
ATE228365T1 (de) 2002-12-15
HUP0103922A3 (en) 2002-08-28
CZ200177A3 (en) 2001-06-13
ES2183583T3 (es) 2003-03-16
CA2336833C (en) 2008-09-23
ID27776A (id) 2001-04-26
DE59903556D1 (de) 2003-01-09
RS49795B (sr) 2008-06-05
US6255329B1 (en) 2001-07-03
KR20010079491A (ko) 2001-08-22
IL140603A0 (en) 2002-02-10
TR200100146T2 (tr) 2001-07-23
EE04296B1 (et) 2004-06-15
WO2000002542A2 (de) 2000-01-20
CZ294087B6 (cs) 2004-10-13
AU762128B2 (en) 2003-06-19
EA200100084A1 (ru) 2001-08-27
PT1093369E (pt) 2003-03-31
BG105112A (bg) 2001-10-31
BG64972B1 (bg) 2006-11-30
KR100557692B1 (ko) 2006-03-07
BR9911768A (pt) 2001-04-03
SK112001A3 (en) 2001-10-08
AU5030399A (en) 2000-02-01
DK1093369T3 (da) 2002-12-16
JP2002520273A (ja) 2002-07-09
AR019896A1 (es) 2002-03-20
PL345842A1 (en) 2002-01-14
NO20010064D0 (no) 2001-01-05
NZ509729A (en) 2003-06-30
EP1093369B1 (de) 2002-11-27
EE200100014A (et) 2002-06-17
DE19830201A1 (de) 2000-01-13
TW592698B (en) 2004-06-21
CA2336833A1 (en) 2000-01-20
NO20010064L (no) 2001-03-02
HUP0103922A2 (hu) 2002-03-28
EA003142B1 (ru) 2003-02-27
YU401A (sh) 2003-10-31
WO2000002542A3 (de) 2000-06-22
HK1037976A1 (en) 2002-03-01
EP1093369A2 (de) 2001-04-25
CN1230168C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
MY117969A (en) Agent with an antidepressive effect comprising pramipexole and sertraline
ATE262895T1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
DE60112055D1 (de) Inhibitoren von gamma-secretase
NO20004803L (no) Smilagening og anzurogenin for behandling av Alzheimers sykdom
ATE237680T1 (de) Transplantation von hämatopoietischen zellen
ATE289781T1 (de) Schlinge mit polsterung zur behandlung von harninkontinenz
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
DE60117046D1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
NO20005290L (no) Riluzol- og levodopa kombinasjoner for behandling av Parkinsons sykdom
ATE402149T1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
NO20054744L (no) Behandling av Alzheimers sykdom
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
DE69739760D1 (de) Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
IL143280A0 (en) Use of riluzole for treating acoustic traumas
FR2802101B1 (fr) Association de cymemazine et d'un neuroleptique atypique
BR0309110A (pt) composições e processo de tratamento da doença de alzheimer
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
DE60118924D1 (de) Verwendung des riluzols oder dessen salzen zur phophylaxe und behandlung der adrenoleukodystrophie